|New System for Eye Surgery a Winner for Carl Zeiss Meditec in India||Downloads and Links|
|Innovative product designed for growth markets successfully launched – Carl Zeiss Meditec now the single-source partner for all systems required for cataract treatment||RTF Documents|
english (50 KB)
|JENA/Germany, 12.02.2009. |
Carl Zeiss Meditec successfully launched its new Visalis 100 system for the surgical treatment of cataracts at the most important ophthalmic meeting in India, the AIOC (All India Ophthalmology Congress) – which took place this year in Jaipur from 5 - 8 February. For the first time, the company chose a growth market for the initial presentation of an innovation.
With this new system, Carl Zeiss Meditec is further expanding its extensive offering of innovative solutions for eye surgery. At the same time, Visalis 100 is the first system the medical technology provider is offering that is specifically tailored to the needs of doctors in emerging markets. With this new product, the company is reacting to the continuing high level of demand for eye surgery systems particularly in Asia, but also in other regions. “The response from doctors was outstanding. The resulting demand clearly confirms our strategy to continue focusing our developments on the requirements of our customers in the various regions of the world,” emphasizes Dr. Michael Kaschke, President and CEO of Carl Zeiss Meditec AG.
The new Visalis 100 system enables the surgical removal of the natural, diseased lens from the eye during cataract surgery (phaco-emulsification). On the introduction of the system, customers were particularly impressed by its outstanding ease of use and its carefully matched performance parameters. The Visalis 100 ideally rounds off Carl Zeiss Meditec’s portfolio of innovative solutions for eye surgery. It can now offer doctors and hospitals a full line of products for cataract treatment including diagnostic instruments, surgical microsopes, a phaco system, intraocular lenses and systems for follow-up care – all from a single source.
“Particularly in the current phase of the global economy, we are placing increased emphasis on innovation that is sharply focused on customer requirements. Visalis 100 is a further example of the implementation of this goal. We recognized the importance of the newly industrializing countries for our growth at an early stage. Therefore, it was a logical step for us to introduce Visalis 100 as our own system specially tailored to the needs of these markets and hence make the promise of the ZEISS brand something that people could more actively experience in these markets,” Dr. Michael Kaschke concluded.
Director Investor Relations
Phone: +49 3641 220-106
Fax: +49 3641 220-117
Director Corporate Communications
Phone: +49 3641 220-331
Fax: +49 3641 220-112
Number: 0043-2009-ENG OP